{"id":"W4283400007","doi":"10.1016/j.esmoop.2022.100520","title":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Pharmaceuticals; National Cancer Institute; Johnson and Johnson; Deciphera Pharmaceuticals; Roche; Bundesministerium für Gesundheit; Exelixis; Meso Scale Diagnostics; Merck; GlaxoSmithKline; Novartis; Pfizer; U.S. Food and Drug Administration; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Melanoma; Gastroenterology; Tyrosine-kinase inhibitor; Metastatic melanoma; Progression-free survival; Oncology; Phases of clinical research; Cancer; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000211429,0.00007661679,0.0002350942,0.00006854772,0.0000507867,0.00001034316,0.0001143011,0.000003649192,0.000530714],"category_scores_gemma":[0.00008070527,0.00005520966,0.00001446691,0.0001446591,0.00004390513,0.0000432237,0.0002713003,0.0001275593,0.000004403234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005822232,"about_ca_system_score_gemma":0.0000783319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000718119,"about_ca_topic_score_gemma":0.00005695634,"domain_scores_codex":[0.9991531,0.00009887975,0.0001604923,0.0001656751,0.0002590822,0.0001628087],"domain_scores_gemma":[0.9995677,0.00007427492,0.00005469619,0.0001711879,0.00003295321,0.00009916167],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008515038,0.001104286,0.9865775,0.00003737225,0.0000839484,0.0001887447,0.0002180521,0.0000117421,0.00001043689,0.000108091,0.0001281564,0.00301667],"study_design_scores_gemma":[0.01462053,0.005430016,0.9790274,0.00007811622,0.00003517527,0.00004383053,0.0001184877,0.0000184612,0.00008130164,0.0000338766,0.0004681599,0.000044646],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957944,0.00001786835,0.000003929896,0.0003064858,0.000009265569,0.001317174,0.0000352885,0.000004351222,0.002511201],"genre_scores_gemma":[0.9974484,0.000001582986,0.002079359,0.00004140615,0.000003107118,0.00007191207,0.00008707831,0.00001010353,0.0002570889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00755006,"threshold_uncertainty_score":0.5810946,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0238742433378822,"score_gpt":0.3035334139704138,"score_spread":0.2796591706325316,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}